Applicant: Kiyotaka Nakano et al. Attorney's Docket No.: 14875-163US1 / C1-A0322P-US

Serial No.: To Be Assigned

Filed : Herewith Page : 3 of 6

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

- 1. (Original) A method of screening for an agonist antibody, which comprises the steps of:
- (a) determining the binding activity of a test antibody and selecting an antibody with binding activity;
  - (b) modifying the antibody selected in step (a); and
- (c) determining the agonistic activity of the modified antibody of step (b) and selecting an antibody with agonistic activity.
- 2. (Original) The screening method of claim 1, wherein the modified antibody is a minibody.
  - 3. (Original) The screening method of claim 2, wherein the minibody is an sc(Fv)2.
- 4. (Currently Amended) The screening method of <u>claim 1</u> any one of claims 1 to 3, wherein the agonistic activity is not determined prior to modifying the test antibody.
- 5. (Currently Amended) The screening method of <u>claim 1</u> any one of claims 1 to 4, wherein the antibody is one against a protein expressed on a cell membrane.
- 6. (Currently Amended) An antibody obtained by the method of <u>claim 1</u> any one of <u>claims 1 to 5</u>.

Applicant: Kiyotaka Nakano et al. Attorney's Docket No.: 14875-163US1 / C1-A0322P-US

Serial No.: To Be Assigned

Filed: Herewith Page: 4 of 6

7. (Original) A method for producing an antibody with agonistic activity, which comprises the steps of:

- (a) determining the binding activity of an antibody and selecting an antibody with binding activity;
  - (b) modifying the antibody selected in step (a);
- (c) determining the agonistic activity of the modified antibody of step (b) and selecting an antibody with agonistic activity;
- (d) introducing a host cell with a vector carrying a DNA that encodes the antibody selected in step (c); and
  - (e) culturing the host cell of step (d).
- 8. (Original) The production method of claim 7, wherein the modified antibody is a minibody.
  - 9. (Original) The production method of claim 8, wherein the minibody is an sc(Fv)2.
- 10. (Currently Amended) The production method of <u>claim 7</u> any one of claims 7 to 9, wherein the agonistic activity is not determined prior to antibody modification.
- 11. (Currently Amended) The production method of <u>claim 7</u> any one of <u>claims 7 to 10</u>, wherein the antibody is one against a protein expressed on a cell membrane.
- 12. (Original) A method of screening for an agonist antibody, wherein the agonistic activity of a test antibody is not determined prior to step (a), and which comprises the steps of:
  - (a) modifying a test antibody; and
- (b) determining the agonistic activity of the modified antibody of step (a) and selecting an antibody with agonistic activity.

Applicant: Kiyotaka Nakano et al. Attorney's Docket No.: 14875-163US1 / C1-A0322P-US

Serial No.: To Be Assigned

¥

Filed: Herewith Page: 5 of 6

13. (Original) The screening method of claim 12, wherein the modified antibody is a minibody.

14. (Original) The screening method of claim 13, wherein the minibody is an sc(Fv)2.